Madrigal Pharmaceuticals (MDGL) CCO reports 910-share sale under plan

Rhea-AI Filing Summary

Madrigal Pharmaceuticals Chief Commercial Officer Carole Huntsman reported routine share sales. On January 26, 2026, a total of 910 shares of Madrigal common stock were sold in two transactions at prices of $492.42 for 340 shares and $494.59 for 570 shares.

The filing explains that 340 shares were sold by the company on her behalf solely to cover tax withholding tied to vesting restricted stock units and occurred automatically. The 570-share sale was executed under a pre-established Rule 10b5-1 trading plan adopted on November 5, 2024. Following these transactions, Huntsman directly beneficially owns 9,122 shares of Madrigal common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Huntsman Carole

(Last) (First) (Middle)

C/O MADRIGAL PHARMACEUTICALS, INC.

200 BARR HARBOR DRIVE, SUITE 200

(Street)

WEST CONSHOHOCKEN PA 19428

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MADRIGAL PHARMACEUTICALS, INC. [ MDGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/26/2026		S(1)		340	D	$492.42	9,692	D
Common Stock	01/26/2026		S(2)		570	D	$494.59	9,122	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.

2. This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

Remarks:

	/s/ Mardi Dier, as Attorney-in-Fact	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the insider in Madrigal Pharmaceuticals (MDGL)'s latest Form 4 filing?

The Form 4 reports transactions by Carole Huntsman, who serves as Chief Commercial Officer of Madrigal Pharmaceuticals, Inc.

How many Madrigal Pharmaceuticals (MDGL) shares did Carole Huntsman sell?

On January 26, 2026, Carole Huntsman had a total of 910 shares of Madrigal common stock sold in two transactions of 340 and 570 shares.

At what prices were the Madrigal Pharmaceuticals (MDGL) shares sold in this Form 4?

The 340 shares were sold at $492.42 per share, and the 570 shares were sold at $494.59 per share, both in Madrigal common stock.

Why were some of Carole Huntsman’s Madrigal (MDGL) shares sold?

The filing states that 340 shares were sold by Madrigal on her behalf to cover tax withholding obligations linked to vesting restricted stock units, and this sale was automatic and not at her discretion.

Was a trading plan used for the Madrigal Pharmaceuticals (MDGL) insider sale?

Yes. The sale of 570 shares was made under a Rule 10b5-1 trading plan adopted by Carole Huntsman on November 5, 2024.

How many Madrigal Pharmaceuticals (MDGL) shares does Carole Huntsman still own after these transactions?

After the reported transactions, Carole Huntsman beneficially owns 9,122 shares of Madrigal Pharmaceuticals common stock, held directly.